MedTrace Logo

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

NCT03279237 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-05-18

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of interventions as a possible treatment for gastroesophageal (GE) junction cancer.

The interventions involved in this study are:

-FOLFIRINOX which is made up of 4 different drugs:

* 5-Fluorouracil (5-FU)
* Oxaliplatin
* Irinotecan
* Leucovorin
* Paclitaxel
* Carboplatin
* Proton Beam Radiation Therapy

Conditions

Interventions

DRUG

Irinotecan

May help shrink tumor before surgery.

DRUG

Oxaliplatin

May help shrink tumor before surgery.

DRUG

Leucovorin

May help shrink tumor before surgery.

DRUG

5-Fluorouracil

May help shrink tumor before surgery.

DRUG

Paclitaxel

Paclitaxel may stop cancer cells from growing and spreading.

RADIATION

Radiation Therapy

May help shrink tumor.

DRUG

Carboplatin

Carboplatin may stop cancer cells from growing.

Sponsors & Collaborators

Principal Investigators

  • Jennifer Wo, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2018-09-26
Completion
2026-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03279237 on ClinicalTrials.gov